Saturday, October 10, 2026

TrueBlue Stock Jump On Monday, Outperforms Market

TrueBlue Stock Jump On Monday, Outperforms Market

(VIANEWS) - The NYSE ended the session with TrueBlue rising 9.98% to $17.64 on Monday, following the last session's downward trend. NYSE slid 0.04% to $15,318.85, following the last session's downward trend on what was a somewhat negative trend exchanging session today.

TrueBlue's last close was $16.04, 30.14% below its 52-week high of $22.96.

About TrueBlue

TrueBlue, Inc., together with its subsidiaries, provides specialized workforce solutions in the United States, Canada, the United Kingdom, Australia, and Puerto Rico. It operates through three segments: PeopleReady, PeopleManagement, and PeopleScout. The company's PeopleReady segment provides general, industrial, and skilled trade staffing services for construction, transportation, manufacturing, retail, hospitality, and renewable energy industries. Its PeopleManagement segment offers contingent, on-site industrial staffing, and commercial driver services, which includes on-site management and recruitment for the contingent industrial workforce of manufacturing, warehouse, and distribution facilities; and recruitment and management of contingent and dedicated commercial drivers to the transportation and distribution industries under the Staff Management, SIMOS Insourcing Solutions, and Centerline Drivers brands. The company's PeopleScout segment provides recruitment process outsourcing, talent advisory services, and managed service provider solutions including sourcing, screening, hiring, and onboarding services; operates Affinix, a technology platform which uses artificial intelligence and machine learning for real-time insights; and contingent labor programs including vendor selection, performance management, compliance monitoring, and risk management. TrueBlue, Inc. was formerly known as Labor Ready, Inc. and changed its name to TrueBlue, Inc. in December 2007. The company is headquartered in Tacoma, Washington.

Earnings Per Share

As for profitability, TrueBlue has a trailing twelve months EPS of $1.43.

PE Ratio

TrueBlue has a trailing twelve months price to earnings ratio of 12.34. Meaning, the purchaser of the share is investing $12.34 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.15%.

Moving Average

TrueBlue's value is higher than its 50-day moving average of $16.72 and under its 200-day moving average of $19.23.

Volatility

TrueBlue's last week, last month's, and last quarter's current intraday variation average was a positive 0.91%, a negative 0.43%, and a positive 1.38%.

TrueBlue's highest amplitude of average volatility was 1.68% (last week), 1.63% (last month), and 1.38% (last quarter).

More news about TrueBlue (TBI).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic Enterprise Software Consolidates: Big Platforms Push Autonomy While Startups Get Absorbed
Enterprise software is shifting toward autonomous, AI-agent-driven products. SAP (Autonomous Enterprise, Joule), Meta (a new Enterprise Platform led by ex-MongoDB CEO Chirantan Desai) and UiPath (raised guidance) are pushing from the top. Meanwhile AI-security and governance startups are being acquired (Fortinet–Virtue AI, Harvey–Guardrails AI, Tiny–Oso Cloud) and seed-stage agent companies keep raising capital (Dextr, Latitude, Groq). Investors such as Norwest's Sean Jacobsohn see finance and ERP back-office software as the easier area to disrupt. Trust and enforced governance are treated as preconditions for regulated sectors like finance, and AI is judged unreliable for calculations.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,365 source documents archived
Query this data → isubstrate.com